Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply chains.
The site, the third new U.S. facility announced by Lilly, will make small-molecule synthetic and peptide medicines, including orforglipron, its first oral GLP-1 weight-loss drug anticipated to receive U.S. approval early next year.
Global pharmaceutical companies have been increasing U.S. investments after President Donald Trump urged the industry to make more medicines domestically rather than importing active ingredients or finished medicines.
Earlier this year, Lilly outlined plans to spend at least $27 billion on four new U.S. manufacturing sites to counter potential drug import duties. Lilly said another location will be announced in the coming weeks.
The company said the construction is slated to begin in 2026, creating about 3,000 construction jobs, with completion targeted for 2032. Lilly also plans 450 roles for engineers, scientists, operations personnel and lab technicians in the area.
CEO David Ricks said the investment advances the onshoring of active pharmaceutical ingredient production to strengthen supply resilience.
The company estimates every dollar invested could generate up to four dollars in local economic activity.
The site was chosen from more than 300 applications, aided by proximity to the HudsonAlpha Institute for Biotechnology, an established bioscience campus supporting workforce training and research, Lilly said.
Alabama Governor Kay Ivey called the project "the largest initial investment in our state's history."
Lilly said the plant will use machine learning, AI and digitally integrated monitoring systems, with automation embedded across operations.
The company also aims to work toward carbon neutrality at the site, said Edgardo Hernandez, Lilly's manufacturing operations head.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026 - 2Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- 3Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- 4NATO needs Ukraine's 'adaptation DNA' and an 'HOV lane' for new war tech, top commander says
- 5A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- Israel faces tough choices over haredi draft exemptions, legal expert warns
- More parents refusing this shot that prevents serious bleeding at birth
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- See the first close-up photos of the moon from NASA's Artemis II mission
- Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage
- Why doing good also makes us feel good, during the holidays and beyond
